Objectives: The axis of osteoprotegerin (OPG), the receptor activator for nuclear factor kB (RANK), and RANK ligand (RANKL) is critical for skeletal biology and calcification process. However, data was scarce on its involvement in intracranial arterial calcification. Methods: Hypertensive patients with at least two cardiovascular risk factors were recruited from Shanghai Xinzhuang Community. Plasma OPG and serum RANKL were measured with ELISA. Brain tomographic angiography was performed with a GE helical CT scanner. Calcification was defined as a focal high-density lesion of at least 120 Hounsfield units at the intracranial arteries. Results: The 831 patients (mean age, 65 years; 54% women) included 465 (56%) with intracranial arterial calcification. Mean clinic blood pressure was 137/72 mmHg and 736 (89%) patients were on anti-hypertensive treatment. Plasma OPG was negatively associated with RANKL (r = − 0.25; P < 0.001). The prevalence of intracranial arterial calcification increased with plasma OPG (49.1%, 56.8% and 61.9% in tertiles 1, 2, and 3, respectively; P = 0.003) and decreased with serum RANKL (61.6%, 54.8% and 49.2%; P = 0.005). In continuous analyses, RANKL, but not OPG (P = 0.57), remained significantly associated with intracranial arterial calcification after adjustment (OR [95%CL] associated with 1-SD increase: 0.63 [0.41, 0.99], P = 0.043). Pathway analysis showed that RANKL mediated part of the association between serum lipids and intracranial arterial calcification (P = 0.008). Conclusion: Circulating RANKL was associated with intracranial arterial calcification, highlighting that it might be a marker for vascular calcification. The involving mechanisms deserve further investigation.
Read full abstract